Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Bone Biologics Corp

Get SEC filing alerts via email and in your feed for Bone Biologics Corp

BBLG BBLGW

Bone Biologics Corp

About Bone Biologics Corp

Bone Biologics Corporation develops recombinant human protein-based medical devices for bone regeneration, focusing on spinal fusion using its proprietary NELL-1 protein combined with demineralized bone matrix (DBM). Targeting orthopedic and spinal surgery markets, the company’s platform aims to improve bone growth outcomes with a safer, targeted approach. Its business model centers on clinical development, regulatory approval, and commercialization of osteopromotive biologics for surgeons and patients with bone defects.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Bone Biologics Corp

1
1
Bone Biologics Corp Bone Biologics Reports Q1 2026 Financial Results with $765,988 Net Loss

Via official filing (AI summary) | 20 days ago | 0 comments

2
1
Bone Biologics Corp Bone Biologics Reports $3.1 Million Net Loss for Fiscal Year 2025, Progresses in Clinical Trials

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Bone Biologics Corp Bone Biologics Reports Q3 2025 Financial Results with Reduced Net Loss

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Bone Biologics Corp Bone Biologics Reports Q2 2025 Financial Results with Net Loss of $740,519

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Bone Biologics Corp Bone Biologics Reports $1.017 Million Net Loss in Q1 2025, No Revenue Generated

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Bone Biologics Corp Bone Biologics Reports 55.25% Reduction in Operating Expenses for Fiscal Year 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
Bone Biologics Corp Bone Biologics Reports Improved Financials, Reduced Losses, and Increased Cash Reserves

Via official filing (AI summary) | over 1 year ago | 0 comments